BRTX Biorestorative Therapies
- 1.365
- -0.095-6.51%
- 1.321
- -0.044-3.24%
Biorestorative Therapies News
Buy Rating on BioRestorative Therapies: Innovative Cell-based Therapies and Strategic Growth Opportunities
Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and BioRestorative Therapies (BRTX)
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) --
Express News | BioRestorative Therapies Shares Are Trading Higher After the Company Announced That It Entered Into a Five-year Exclusive Supply Agreement With Cartessa Aesthetics
Express News | BioRestorative Therapies Announces Commercial Agreement With Cartessa,A Medical Aesthetics Technology Provider
Express News | BioRestorative Therapies Inc: Exclusive, Five-Year Agreement Includes BioRestorative Supplying Its Initial Commercial Product to Cartessa
Express News | BioRestorative Therapies Announces Transformative Commercial Agreement With Cartessa, a Global Leader in Medical Aesthetics Technology
Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances
Express News | BioRestorative Therapies Inc : Maxim Group Cuts Target Price to $6 From $10
Biotech Catches Major Premarket Bid Following FDA Clearance
Express News | BioRestorative Therapies Shares up 9.5% After U.S. FDA Clears Change to Cell Therapy's Mid-Stage Study
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial
BioRestorative Therapies (BRTX) said Tuesday that the US Food and Drug Administration has cleared an amendment to the protocol of the current phase 2 trial of its cell therapy candidate, BRTX-100, to
Market-Moving News for April 16th
CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As First Indication; Discontinued Enrollment In Its B-NHL Study To Focus On
Why BioRestorative Therapies Is Rising In Pre-market?
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersDynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.4
Express News | BioRestorative Therapies Shares Are Trading Higher After the Company Announced FDA Clearance of Its Phase 2 BRTX-100 Clinical Study Protocol Amendment
Express News | BioRestorative Therapies Inc - Protocol Amendment Removes Saline Injection in Control Arm of Study and Replaces It With a Sham Injection
Express News | BioRestorative Therapies Announces FDA Clearance of Phase 2 Brtx-100 Clinical Study Protocol Amendment
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration ("FDA") has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company's lead cell therapy candidate, in treating chronic lumbar disc disease ("cLDD").
10 Micro-Cap Healthcare Stocks Insiders Are Buying
Analysis
Price Target
No Data
